Quantitative proteomic analysis of down syndrome biomarkers in maternal serum using isobaric tags for relative and absolute quantification (iTRAQ)

• Published in: Gynecological endocrinology Vol. 36; no. 6; pp. 489 - 495
• Main Authors: Zhao, Sheng-Long, Liu, Xiao-Wei, Wu, Shao-Wen, Zheng, Yuan-Yuan, Zhang, Wei-Yuan
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 02.06.2020
• Subjects: Adult; aneuploidy; Biomarkers - analysis; Biomarkers - blood; Case-Control Studies; Down Syndrome - blood; Down Syndrome - diagnosis; Female; Humans; Maternal Age; Maternal Serum Screening Tests - methods; Predictive Value of Tests; Pregnancy; Prenatal diagnosis; Prenatal Diagnosis - methods; proteomics; Proteomics - methods; trisomy 21; aneuploidy; Prenatal diagnosis; proteomics; trisomy 21
• ISSN: 0951-3590; 1473-0766
• DOI: 10.1080/09513590.2019.1696302

Prenatal diagnosis of Down syndrome (DS) is based on calculated risk involving maternal age, biochemical and ultrasonographic markers, and, more recently, cell-free DNA (cfDNA). The present study was designed to identify Down Syndrome biomarkers in maternal serum. We quantified the changes in maternal serum protein levels between 10 non-pregnant women, 10 pregnant women with healthy fetuses, and 10 pregnant women with DS fetuses using isobaric tags for relative and absolute quantification (iTRAQ). We subsequently conducted a Gene Ontology (GO) analysis. A total of 470 proteins were identified, 11 of which had significantly different serum levels between the DS fetus group and Healthy fetuses group. Our data shows the identified proteins may be relevant to DS and constitute potential DS biomarkers.